These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27904739)

  • 1. Review of siltuximab in the treatment of multicentric Castleman's disease.
    Sarosiek S; Shah R; Munshi NC
    Ther Adv Hematol; 2016 Dec; 7(6):360-366. PubMed ID: 27904739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease.
    Sitenga J; Aird G; Ahmed A; Silberstein PT
    Patient Relat Outcome Meas; 2018; 9():35-41. PubMed ID: 29391839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
    van Rhee F; Wong RS; Munshi N; Rossi JF; Ke XY; Fosså A; Simpson D; Capra M; Liu T; Hsieh RK; Goh YT; Zhu J; Cho SG; Ren H; Cavet J; Bandekar R; Rothman M; Puchalski TA; Reddy M; van de Velde H; Vermeulen J; Casper C
    Lancet Oncol; 2014 Aug; 15(9):966-74. PubMed ID: 25042199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siltuximab: a new option for the management of Castleman's disease.
    Barquero N
    Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
    Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
    Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients.
    Prescrire Int; 2016 Mar; 25(169):61-4. PubMed ID: 27152394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
    van Rhee F; Rothman M; Ho KF; Fleming S; Wong RS; Fosså A; Dispenzieri A; Cavet J; Munshi N; Vermeulen J; Casper C
    Patient; 2015 Apr; 8(2):207-16. PubMed ID: 25736164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases.
    Komaba H; Nakazawa T; Yamaguchi Y; Kumagai S; Fukagawa M
    NDT Plus; 2008 Dec; 1(6):423-426. PubMed ID: 28656995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
    Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
    Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of Castleman's disease with siltuximab - case report and review of literature.
    Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
    Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiopathic multicentric Castleman's disease: a systematic literature review.
    Liu AY; Nabel CS; Finkelman BS; Ruth JR; Kurzrock R; van Rhee F; Krymskaya VP; Kelleher D; Rubenstein AH; Fajgenbaum DC
    Lancet Haematol; 2016 Apr; 3(4):e163-75. PubMed ID: 27063975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical development of siltuximab.
    Davis CC; Shah KS; Lechowicz MJ
    Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Siltuximab and 1,927 nm Fractional Laser for the Treatment of Cutaneous Manifestations in Castleman's Disease: The Role of Dermoscopy and Reflectance Confocal Microscopy for Lesion Evaluation.
    Paolino G; Ardigò M; Della-Torre E; Moroni L; Rizzo N; Nicola MRD; Bianchi VG; Dagna L; Ramirez GA; Mercuri SR
    Case Rep Dermatol; 2024; 16(1):97-101. PubMed ID: 38590388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoids combined with tofacitinib in the treatment of Castleman's disease: A case report.
    Liu XR; Tian M
    World J Clin Cases; 2022 Oct; 10(29):10794-10802. PubMed ID: 36312499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the Complexities of Idiopathic Multicentric Castleman Disease and Its Multi-systemic Associations: A Case Report.
    Palvia AR; Saha P; Nandi AR; Damera AR; Suresh A
    Cureus; 2024 Jul; 16(7):e64935. PubMed ID: 39161530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
    Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
    AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
    Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
    Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. General anesthesia in a patient with multicentric Castleman's disease: a case report.
    Son HW; Huh IY; Lee SH; Kim AS; Park SH; Kim DY
    Korean J Anesthesiol; 2015 Jun; 68(3):304-8. PubMed ID: 26045937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
    Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Castleman's disease: from basic mechanisms to molecular therapeutics.
    El-Osta HE; Kurzrock R
    Oncologist; 2011; 16(4):497-511. PubMed ID: 21441298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.